0001140361-17-045017.txt : 20171205 0001140361-17-045017.hdr.sgml : 20171205 20171205125542 ACCESSION NUMBER: 0001140361-17-045017 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171201 FILED AS OF DATE: 20171205 DATE AS OF CHANGE: 20171205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McCarthy Sean A. CENTRAL INDEX KEY: 0001654058 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37587 FILM NUMBER: 171239172 MAIL ADDRESS: STREET 1: 343 OYSTER POINT BLVD. STREET 2: SUITE 100 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CytomX Therapeutics, Inc. CENTRAL INDEX KEY: 0001501989 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273521219 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650.515.3185 MAIL ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc1.xml FORM 4 X0306 4 2017-12-01 0 0001501989 CytomX Therapeutics, Inc. CTMX 0001654058 McCarthy Sean A. C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., SUITE 400 SOUTH SAN FRANCISCO CA 94080 1 1 0 0 President and CEO Common Stock 2017-11-30 5 A 0 398 12.1465 A 4643 D Common Stock 2017-12-01 4 M 0 4100 0.945 A 8743 D Common Stock 2017-12-01 4 M 0 10240 1.1339 A 18983 D Common Stock 2017-12-01 4 S 0 14340 20.60 D 4643 D Common Stock 158737 I See footnote Stock Option (right to buy) 0.945 2017-12-01 4 M 0 4100 0.00 D 2023-02-25 Common Stock 4100 115193 D Stock Option (right to buy) 1.1339 2017-12-01 4 M 0 10240 0.00 D 2021-09-20 Common Stock 10240 356721 D 398 shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.42 to $20.78, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Held in McCarthy Family Trust dated August 9, 2001, Sean A. McCarthy and Jeanette J. McCarthy, Trustees. 100% of the shares subject to the option are fully vested and exercisable. /s/ Cynthia J. Ladd, as Attorney-in-Fact for Sean A. McCarthy 2017-12-05